Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 6:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2593–2616 of 4,249 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Study Product Clear all

Conditions: Adjunctive Treatment of Major Depressive Disorder (MDD)
Interventions: CLE-100, Placebo; Drug
Lead sponsor: Clexio Biosciences Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 23
States / cities: La Jolla, California • Lafayette, California • Upland, California + 20 more

Conditions: NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis
Interventions: Satralizumab, Placebo; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 12 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 11
States / cities: Birmingham, Alabama • Newport Beach, California • San Francisco, California + 7 more

Conditions: Healthy Volunteers
Interventions: [11C] raclopride, liquid nutritive stimulus, Tasteless Oral Stimulus Solution, Minimally Processed Diet, Ultra Processed Diet, Baseline Diet; Drug · Other
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Treatment Outcome
Interventions: Vortioxetine, Escitalopram, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 53
States / cities: Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 50 more

Conditions: Sexual Desire
Interventions: Active Sexual Health Product 1, Active Sexual Health Product 2, Active Sexual Health Product 3, Placebo Sexual Health Control Product; Dietary Supplement
Lead sponsor: Radicle Science; Industry
Eligibility: 21 Years to 105 Years · Female only
Enrollment: 1,100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Del Mar, California

Conditions: Type 2 Diabetes, End Stage Renal Disease
Interventions: Placebo, Sitagliptin; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 70 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Intraocular Lens Replacement
Interventions: OMS302, Placebo; Drug
Lead sponsor: Omeros Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 16
States / cities: Chandler, Arizona • Glendale, Arizona • Los Angeles, California + 13 more

Conditions: Aging
Interventions: Rapamycin, Everolimus, Placebo; Drug · Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 65 Years to 90 Years
Enrollment: 194 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Intracerebral Hemorrhage
Interventions: Albumin, Placebo, Brain MRI with and without contrast; Drug · Procedure
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Post Acute COVID-19 Syndrome, Long COVID, Long Covid19, COVID-19 Recurrent, Post-Acute COVID-19, Post-Acute COVID-19 Infection, SARS-CoV2 Infection, Post Acute Sequelae of COVID-19, Dysautonomia, Dysautonomia Like Disorder, Dysautonomia Orthostatic Hypotension Syndrome, Post COVID-19 Condition, Post-COVID Syndrome, Post COVID-19 Condition, Unspecified, Post-COVID-19 Syndrome
Interventions: stellate ganglion block with 0.5% bupivacaine; Drug
Lead sponsor: Jonathann Kuo, MD; Other
Eligibility: 18 Years to 100 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: Mushroom blend, Placebo; Dietary Supplement · Other
Lead sponsor: University of South Carolina; Other
Eligibility: 30 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Malaria
Interventions: DM1157, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Asthma
Interventions: GW685698X; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 627 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 94
States / cities: Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 82 more

Conditions: Atopic Dermatitis, Eczema
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: 0 Months to 17 Years
Enrollment: 505 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2027
U.S. locations: 4
States / cities: Chicago, Illinois • Northbrook, Illinois • New York, New York

Conditions: Renal Insufficiency, Chronic
Interventions: 6R-BH4, 6R-BH4 placebo, Folic acid, Exercise training, Stretching, Histidine and beta-alanine supplementation, Histidine and beta-alanine placebo; Drug · Other · Dietary Supplement
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 3
States / cities: Atlanta, Georgia • Decatur, Georgia

Conditions: Gastroparesis
Interventions: PCS12852, Placebo; Drug
Lead sponsor: Processa Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 9
States / cities: Lomita, California • San Diego, California • Miami, Florida + 5 more

Conditions: Bunion, Hallux Valgus
Interventions: SKY0402, Placebo; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: HIV Infections, Lipodystrophy, Hyperinsulinemia
Interventions: Metformin hydrochloride, Rosiglitazone maleate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 34
States / cities: Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 20 more

Conditions: ADHD, Substance Abuse
Interventions: Methylphenidate (OROS-MPH), Methylphenidate (OROS-MPH) - Placebo; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 13 Years to 18 Years
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 12
States / cities: Denver, Colorado • Jacksonville, Florida • St. Petersburg, Florida + 9 more

Conditions: Pulmonary Hypertension
Interventions: Iloprost PD-6, Iloprost PD-15; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 12
States / cities: Phoenix, Arizona • La Jolla, California • Iowa City, Iowa + 8 more

Conditions: Solid Tumor, Hematologic Malignancy
Interventions: Multilevel Adherence Intervention; Behavioral
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Painful Bladder Syndrome, Interstitial Cystitis, Bladder Pain Syndrome
Interventions: URG101, Placebo; Drug
Lead sponsor: Urigen; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 6
States / cities: Glendora, California • San Diego, California • Cartersville, Georgia + 1 more

Conditions: Epilepsy, Generalized, Epilepsy, Absence
Interventions: NPT 2042, Placebo; Drug · Other
Lead sponsor: NeuroPro Therapeutics, Inc.; Industry
Eligibility: 16 Years to 75 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Intermittent Claudication, Peripheral Artery Disease
Interventions: GFH312, Placebo; Drug · Other
Lead sponsor: Zhejiang Genfleet Therapeutics Co., Ltd.; Industry
Eligibility: 40 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Davenport, Iowa

Search by objective public record fields.

A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis

Effects of Ad Libitum Ultra-Processed Diet on Brain Dopamine in Humans

Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction

Radicle Women's Sexual HealthTM CIX: A Study Assessing the Impact of Health and Wellness Products on Sexual Health and Related Health Outcomes

Using Sitagliptin as a Treatment to Prevent New Onset Diabetes After Kidney Transplantation

Safety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification

RESTOR: PK/PD mTORi Inhibition in Older Adults

Albumin for Intracerebral Hemorrhage Intervention

Dual Sympathetic Blocks for Patients Experiencing Sympathetically-Mediated Symptoms From Long COVID

Effects of a Mushroom Blend on Gastrointestinal Symptoms and the Microbiome

Safety and Pharmacokinetics Study of DM1157 to Treat Malaria

A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Moderate-Dose ICS Therapy.

Defining the Skin and Blood Biomarkers of Pediatric Atopic Dermatitis

Neurovascular Transduction During Exercise in Chronic Kidney Disease

Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With Moderate to Severe Gastroparesis

Study of Postoperative Analgesia in Bunionectomy

Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities

Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents With Substance Use Disorders (SUD)

The "Power 15 Study": Safety Study of Inhalation of Ventavis With the Power Disc-15 Setting

Implementation of an Oral Chemotherapy Adherence Intervention

Study of URG101 in Painful Bladder Syndrome and Interstitial Cystitis

A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures

A Study of GFH312 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication (IC)